Omecamtiv mecarbil fails to improve exercise capacity in HFrEF patients: JAMA Dr. Kamal Kant Kohli21 Aug 2022 2:30 PMUSA: Omecamtiv mecarbil does not notably improve exercise capacity across a 20-week span in patients with chronic heart failure with reduced...
Omecamtiv mecarbil reduces CV death among patients with severe systolic heart failure: JAMA MD Editorial Team26 Oct 2021 3:30 AMHeart failure with reduced ejection fraction is a progressive clinical syndrome, and many patients' condition worsen over time despite...
Omecamtiv mecarbil of greater therapeutic benefit in HF patients with severely reduced EF: Study Hina Zahid3 Jun 2021 3:30 AM Delhi: The experimental omecamtiv mecarbil greatly reduced heart failure hospitalizations among HFrEF patients as their baseline ejection...
Omecamtiv mecarbil reduces CV death, heart failure risk in HFrEF patients: NEJM Medha Baranwal14 Jan 2021 2:51 PMUSA: The administration of omecamtiv mecarbil in patients with heart failure and a reduced ejection fraction (HFrEF) reduces the risk of a composite...
FDA grants fast Track designation to omecamtiv mecarbil for HFrEF Dr. Kamal Kant Kohli9 May 2020 3:39 AMTHOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO--Heart failure is a serious condition that affects more than 64 million people worldwide about half of...
Cytokinetics, Amgen drug shows promise in heart failure study Pooja Bhatia Bhatia9 Nov 2015 4:05 AMOrlando: An experimental heart failure drug being developed by Cytokinetics Inc and Amgen Inc demonstrated several beneficial cardiac function effects...
